Project Update

Futura Medical PLC
09 April 2008


                                  

For Immediate Release                                             9 April 2008

                                        
                               Futura Medical Plc
                          ('Futura' or 'the Company')


                     Update on topical pain relief project

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative
products for consumer healthcare, can provide the following update on its
topical pain relief project, TPR100, using Futura's proprietary trans-dermal
delivery technology, DermaSys(R).

Completion of clinical studies to evaluate drug delivery using Futura's Dermasys
(R) technology has been extended to complete formulation optimisation.
Commercial negotiations are continuing on a non-exclusive basis.

We will provide further updates to shareholders at the earliest opportunity.


For further information:

Futura Medical plc
James Barder, Chief Executive                 Tel: [phone]
mail to:                                        www.futuramedical.co.uk
[e-mail]

Canaccord Adams
Ryan Gaffney / Adria Da Breo                  Tel: [phone]


Media enquiries:
Buchanan Communications
Mark Court / Rebecca Skye Dietrich            Tel: [phone]
                                                                   


Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for
consumer healthcare. The Company is developing a portfolio of products and its
strategy is to license their manufacture and distribution to major
pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of
the London Stock Exchange.

www.futuramedical.co.uk



                      This information is provided by RNS
            The company news service from the London Stock Exchange